Arpida Provides Comprhensive Overview of Pivotal Phase III ...( REINACH Switzerland April 17 /- I...),Health

REINACH, Switzerland, April 17 /PRNewswire-FirstCall/ -- In order to give a comprehensive overview of the results of the two pivotal Phase III trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI), Arpida Ltd. (SWX: ARPN) today provides a table with the key data from the trials. Part of the data has already been published in previous press releases, while some additional statistical data are included that have not been announced before.

The efficacy data confirm the achievement of the pre-specified primary endpoint in the relevant populations in both trials. Moreover, pooling of the data from the two trials allows further powering and demonstrates that the pre-specified efficacy endpoint is achieved. Furthermore, the microbiological eradication rates for MRSA observed with iclaprim were very similar to those of the comparator. Finally, iclaprim showed a safety profile in the studies which was compatible with treatment of patients with cSSSI and compared favourably with the comparator.

Based on the Phase III results and on those of other studies carried out, Arpida is confident that intravenous iclaprim has compelling properties, both in terms of efficacy and safety. Arpida has filed a New Drug Application with the US FDA for intravenous iclaprim in cSSSI in March 2008.

The complete press release, including appendix, is available on http://www.arpida.com

Conference Call

Arpida will host a conference call to discuss this news release, 17 April

2008, at 8.30 am CET. The dial-in numbers are:

+41(0)91-610-56-00 (Europe)

+44(0)207-107-0611 (UK)

+1-866-291-4166 (USA)

The conference call (Call ID 15104, followed by the #) will be available

for play-back for 48 hours after the call by dialling:

+41(0)91-612-43-30 (Europe)

+44(0)207-108-6233 (UK)

+1-866-416-2558 (USA)

About Arpid
'/>"/>